Compare Consumer Discretionary Select Sector SPDR Fund (XLY) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Consumer Discretionary Select Sector SPDR Fund vs Zimmer Biomet Holdings Inc — how do they compare? Consumer Discretionary Select Sector SPDR Fund trades at $114.85, while Zimmer Biomet Holdings Inc trades at $90.03 (market cap $17.36B). The key difference: Zimmer Biomet Holdings Inc pays a 1.07% dividend while Consumer Discretionary Select Sector SPDR Fund pays none, and Consumer Discretionary Select Sector SPDR Fund is trading nearer its 52-week high, Zimmer Biomet Holdings Inc nearer its low. Which is the better fit depends on your goals.
| XLY | ZBH | |
|---|---|---|
52-Week High | $124.52 | $107.71 |
52-Week Low | $105.64 | $79.58 |
Market Cap | — | $17.36B |
Sector | — | Health |
Enterprise Value | — | $24.40B |
Dividend Yield | — | 1.07% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Consumer Discretionary Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.
Read more on XLY →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
